The average one-year price target for Context Therapeutics (NasdaqCM:CNTX) has been revised to $5.78 / share. This is an increase of 13.33% from the prior estimate of $5.10 dated February 21, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $7.35 / share. The average price target represents an increase of 127.11% from the latest reported closing price of $2.54 / share.
What is the Fund Sentiment?
There are 43 funds or institutions reporting positions in Context Therapeutics. This is an decrease of 6 owner(s) or 12.24% in the last quarter. Average portfolio weight of all funds dedicated to CNTX is 0.27%, an increase of 20.67%. Total shares owned by institutions decreased in the last three months by 8.15% to 65,197K shares.
What are Other Shareholders Doing?
MPM Oncology Impact Management holds 10,679K shares representing 11.62% ownership of the company. In its prior filing, the firm reported owning 14,706K shares , representing a decrease of 37.70%. The firm decreased its portfolio allocation in CNTX by 22.98% over the last quarter.
Blue Owl Capital Holdings holds 7,433K shares representing 8.09% ownership of the company. In its prior filing, the firm reported owning 7,408K shares , representing an increase of 0.34%. The firm decreased its portfolio allocation in CNTX by 63.41% over the last quarter.
Deep Track Capital holds 7,419K shares representing 8.08% ownership of the company. No change in the last quarter.
Nextech Invest holds 7,419K shares representing 8.08% ownership of the company. No change in the last quarter.
Avidity Partners Management holds 5,505K shares representing 5.99% ownership of the company. In its prior filing, the firm reported owning 8,982K shares , representing a decrease of 63.16%. The firm increased its portfolio allocation in CNTX by 17.86% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
